Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of tNGS on CAP Patients With Initial Treatment Failure
Sponsor: Capital Medical University
Summary
This is a multicenter, randomized controlled trial designed to evaluate the impact of tNGS in patients with community-acquired pneumonia who experience initial treatment failure.
Official title: Impact of Targeted Next-generation Sequencing on Hospitalized Patients With Community-acquired Pneumonia and Initial Treatment Failure
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
524
Start Date
2026-04-10
Completion Date
2028-02-28
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
Targeted next-generation sequencing
Bronchoalveolar lavage fluid (BALF) or sputum samples will be collected within 72 hours after randomization and sent for targeted next-generation sequencing (tNGS). The test results will be reported to the attending physician within 1-2 days.
Conventional microbiological testing
Bronchoalveolar lavage fluid (BALF) or sputum samples will be collected within 72 hours after randomization and sent for conventional microbiological testing. The type of conventional microbiological testing will be determined by the attending physician, and test results will be reported in approximately one week
Follow-up at Day 30
A telephone visit will be conducted on or around Day 30 for study participants who are discharged or transferred to another hospital due to disease exacerbation, to collect information on survival, ICU admissions, mechanical ventilation, and medical costs.
Locations (1)
China-Japan Friendship hospital
Beijing, Beijing Municipality, China